Basic keyword search: keyword/text (minimum 3 characters)
Advanced keyword search:
1) keyword1/text1 AND keyword2/text2 (=search results must consist of both keywords/texts! 1 and 2!)
2) Keyword1/text1 OR keyword2/text2 (=search results must consist of either 1 or 2)

Reset
2019
Wienke, J., Bellutti Enders, F., Lim, J., Mertens, J., Van Den Hoogen, L., Wijngaarde, C., Yeo, J., Meyer, A., Otten, H., Fritsch-Stork, R., Kamphuis, S., Hoppenreijs, E., Armbrust, W., Van Den Berg, J., Hissink Muller, P., Tekstra, J., Hoogendijk, J., Deakin, C., De Jager, W., Van Roon, J., Van Der Pol, W., Nistala, K., Pilkington, C., De Visser, M., Arkachaisri, T., Radstake, T., Van Der Kooi, A., Nierkens, S., Wedderburn, L., Van Royen-Kerkhof, A., & Van Wijk, F. (2019). Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multi-cohort validation. Arthritis Rheumatol, 5(.), .. doi: 10.1002/art.40881
2018
Cuppen, B. V. J., Rossato, M., Fritsch-Stork, R. D. E., Concepcion, A. N., Linn-Rasker, S. P., Bijlsma, J. W. J., Van Laar, J. M., Lafeber, F. P. J. G., Radstake, R. T., & Investigators All Sru, .. (2018). RNA sequencing to predict response to TNF-α inhibitors reveals possible mechanism for nonresponse in smokers. Expert Rev Clin Immunil, 14(7), 623-633. doi: 10.1080/1744666X.2018.1480937
Cuppen, B., Fritsch-Stork, R., Eekhout, I., De Jager, W., Marijnissen, A., Bijlsma, J., Custers, M., Van Laar, J., Lafeber, F., Welsing, P., & All Society For Rheumatology Research Utrecht, (. I. (2018). Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score. Scand J Rheumatol, 47(1), 12-21. doi: 10.1080/03009742.2017.1309061
Hartman, E., Van Royen-Kerkhof, A., Jacobs, J., Welsing, P., & Fritsch-Stork, R. (2018). Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-an. Autoimmun Rev., 17(3), 316-322. doi: 10.1016/j.autrev.2018.01.007
Van Den Hoogen, L. L., Palla, G., Bekker, C. P. J., Fritsch-Stork, R. D. E., Radstake, T. R. D. J., & Van Roon, J. A. G. (2018). Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores. RMD Open, 4(2), Epub. doi: 10.1136/rmdopen-2018-000693
Van Den Hoogen, L., Van Der Heijden, E., Hillen, M., Mertens, J., Fritsch-Stork, R., Radstake, T., & Van Roon, J. (2018). Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Ann Rheum Dis, 80(.), .. doi: 10.1136/annrheumdis-2018-214651
Van Den Hoogen, L., Van Roon, J., Mertens, J., Wienke, J., Lopes, A., De Jager, W., Rossato, M., Pandit, A., Wichers, C., Van Wijk, F., Fritsch-Stork, R., & Radstake, T. (2018). Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis, 77(12), 1810-1814. doi: 10.1136/annrheumdis-2018-213497
Van Der Linden, M., Van Den Hoogen, L., Westerlaken, G., Fritsch-Stork, R., Van Roon, J., Radstake, T., & Meyaard, L. (2018). Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology, 57(7), 1228–1234. doi: 10.1093/rheumatology/key067
2017
Cuppen, B., Pardali, K., Kraan, M., Marijnissen, A., Yrlid, L., Olsson, M., Bijilsma, J., Lafeber, F., & Fritsch-Stork, R. (2017). Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment. Rheumatol Int, 37(4), 531-536. doi: 10.1007/s00296-017-3653-1
Kok, H., Van Den Hoogen, L., Van Roon, J., Adriaansen, E., Fritsch-Stork, R., Goldschmeding, R., Radstake, T., & Bovenschen, N. (2017). Systemic and local granzyme B levels are associated with disease activity, kidney damage and interferon signature in systemic lupus erythematosus. Rheumatology (Oxford), 56(12), 2129-2134. doi: 10.1093/rheumatology/kex332
Kroese, S., Abheiden, C., Blomjous, B., Van Laar, J., Derksen, R., Bultink, I., Voskuyl, A., Lely, A., De Boer, M., De Vries, J., & Fritsch-Stork, R. (2017). Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study. J Immunol Res., vol. 2017, epub ahaed of print. doi: 10.1155/2017/8245879
Kroese, S., De Hair, M., Limper, M., Lely, A., Van Laar, J., Derksen, R., & Fritsch-Stork, R. (2017). Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births. J Immunol Res, vol.2017, Article ID 2810202. doi: 10.1155/2017/2810202
Otten, H., Brummelhuis, W., Fritsch-Stork, R., Leavis, H., Wisse, B., Van Laar, J., & Derksen, R. (2017). Measurement of antinuclear antibodies and their fine specificities: time for a change in strategy?. Clin Exp Rheumatol, 35(3), 462-470.
Teng, Y., Bredewol, E., Rabelink, T., Huizinga, T., Eikenboom, H., Limper, M., Fritsch-Stork, R., Bloemenkamp, K., & Sueters, M. (2017). An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology (Oxford), Epub ahead of print, .. doi: 10.1093/rheumatology/kex374
Yousef Yengej, F., Van Royen-Kerkhof, A., Derksen, R., & Fritsch-Stork, R. (2017). The development of offspring from mothers with systemic lupus erythematosus. A systematic review. Autoimmun Rev., 16(7), 701-711. doi: 10.1016/j.autrev.2017.05.005
2016
Cuppen, B. V., Rossato, M., Fritsch-Stork, R. D., Schenk, Y., Bijlsma, J. J., Radstake, T. R., & Lafeber, F. P. J. G. (2016). Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?. Arthritis Research and Therapy, 18(1), 189. doi: 10.1186/s13075-016-1085-z (IF: 4.2)
Fritsch-Stork, R., Silva-Cardoso, S., Groot Koerkamp, M., Broen, J., Lafeber, F., & Bijlsma, J. (2016). Expression of ERAP2 and LST1 is increased before start of therapy in rheumatoid arthritis patients with good clinical response to glucocorticoids. Clin Exp Rheumatol, 34(4), 685-689. http://www.clinexprheumatol.org/abstract.asp?a=9832
Fu, J., Cuppen, B., Welsing, P., Van Wietmarschen, H., Harms, A., Berger, R., Koval, S., Fritsch-Stork, R., Bijlsma, J., Hankemeier, T., Van Der Greef, J., & Lafeber, F. (2016). Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment. Inflammopharmacology, 24(6), 397-402. doi: 10.1007/s10787-016-0284-1
Fu, J., Cuppen, B. V., Welsing, P. M. J., Van Wietmarschen, H., Harms, A. C., Berger, R., Koval, S., Fritsch-Stork, R. D. E., Bijlsma, J. W. J., Hankemeier, T., Van Der Greef, J., & Lafeber, F. P. J. G. (2016). Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment. Inflammopharmacology, 24(6), 397–402. doi: doi:10.1007/s10787-016-0284-1 (IF: 2.59)
Van Den Hoogen, L. L., Fritsch-Stork, R. D., Versnel, M. A., Derksen, R. H. W., Van Roon, J. A. G., & Radstake, T. R. D. (2016). Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Annals of the Rheumatic Diseases, 75(12), e82-e82. doi: doi:10.1136/annrheumdis-2016-210485 (IF: 12.8)
Van Den Hoogen, L. L., Van Roon, J. A., Radstake, T. R., Fritsch-Stork, R. D., & Derksen, R. H. (2016). Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev., 15(1), 50-60. doi: 10.1016/j.autrev.2015.08.011
Van Den Hoogen, L., Fritsch-Stork, R., Versnel, M., Derksen, R., Van Roon, J., & Radstake, T. (2016). Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Ann Rheum Dis, 75(12), e81. doi: 10.1136/annrheumdis-2016-210485